news

CUPERTINO, Calif., May 10, 2010 /PRNewswire via COMTEX/ –DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2010. Total revenues were $7.7 million for the three months ended March 31, 2010 and $6.2 million for the three months ended March 31, 2009. Net loss for the three months ended […]

CUPERTINO, Calif., May 4, 2010 /PRNewswire via COMTEX/ –In conjunction with DURECT Corporation’s (Nasdaq: DRRX) first quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, May 10, 2010 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

CUPERTINO, Calif., April 7, 2010 /PRNewswire via COMTEX/ –DURECT Corporation (Nasdaq: DRRX) announced today that its licensee, King Pharmaceuticals (NYSE: KG), has begun a Phase IIb clinical trial to evaluate ELADUR(TM) (TRANSDUR(TM)-Bupivacaine) for the treatment of chronic low back pain. ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3

CUPERTINO, Calif., March 17, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Barclays Capital Global Healthcare Conference on Wednesday, March 24 at 8:30 am Eastern Time. The conference is being held at the Loews Miami Hotel, Florida. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live

CUPERTINO, Calif., March 1, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the Cowen and Company 30th Annual Healthcare Conference on Monday, March 8 at 3:15 pm Eastern Time. The conference is being held at the Marriott Copley

CUPERTINO, Calif., Feb 24, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2009. Total revenues were $4.9 million for the three months ended December 31, 2009 and $7.7 million for the three months ended December 31, 2008. Net loss for the

CUPERTINO, Calif., Feb 22, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that Nycomed and DURECT have amended the Development and License Agreement entered into between the parties in 2006 covering the development and commercialization of POSIDUR(TM) (also known as SABER(TM)-Bupivacaine or OPTESIA(TM)), an investigational drug for the treatment of post-surgical pain.

CUPERTINO, Calif., Feb 17, 2010 /PRNewswire via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, February 24, 2010 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo:

BESST (Bupivacaine Effectiveness and Safety in SABER(TM) Trial) Targets Post-Surgical PainCUPERTINO, Calif., Jan 19, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has begun dosing patients in its U.S. pivotal Phase III clinical trial to evaluate POSIDUR(TM) (SABER(TM)-Bupivacaine), an investigational drug, for the treatment of post-surgical pain. The pivotal trial,

CUPERTINO, Calif., Dec 17, 2009 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today positive results from a 60 patient Phase IIb clinical trial of POSIDUR(TM), a proprietary product under development for the treatment of post-surgical pain. Top line results from this study of patients undergoing arthroscopic shoulder surgery showed a consistent reduction of